Difference between revisions of "Part:BBa K1694015"
 
(8 intermediate revisions by 2 users not shown)
Line 4: Line 4:
  
 
<h1>'''Introduction:'''</h1>
 
<h1>'''Introduction:'''</h1>
−
[[File:H11.png|200px|thumb|right|'''Fig.1''' Ompa-N-scfv(Anti-HER2)]]
+
[[File:H11.png|200px|thumb|right|'''Fig.1''' OmpA-N-scFv (anti-HER2)]]
−
To display the antibody outside the ''E. coli'', we used Lipoprotein-Outer membrane protein A (Lpp-OmpA). According to the paper reference <sup>[1]</sup>, we chose the first 9 amino acid of Lpp and the 46~159 amino acid of OmpA.
+
To display the <html><a href="https://parts.igem.org/Part:BBa_K1694005"> scFv</a></html> outside the ''E. coli'', we used <html><a href="https://parts.igem.org/Part:BBa_K1694002">Lipoprotein-Outer membrane protein A (Lpp-OmpA)</a></html>. According to the paper reference, we chose the first 9 amino acid of Lpp and the 46~159 amino acid of OmpA.
 
<br>
 
<br>
−
In order to easily change the various scFv DNA sequence, we added a ''NcoI'' restriction site between OmpA and scFv.
+
In order to easily change various scFv DNA sequence, we added a ''NcoI'' restriction site between OmpA and scFv. When designing XbaI-SpeI restriction site between Lpp-OmpA and scFv, it will cause a mixed site. Therefore, the NcoI restriction site rather than the EX-SP restriction site was designed.
 +
 
 
<br>
 
<br>
−
The Fig.2 showed how we integrate Lpp-OmpA-N and scFv into ''NcoI'' restriction site. We used restriction enzyme ''NcoI'' to digest the upstream and downstream parts. After ligating two digest products, there are no M site in Lpp-OmpA-N-scFv.
+
The Fig.2 showed how we design ''NcoI'' restriction site. First, we digest Lpp-OmpA part with EcoRI and NcoI, scFv part with NcoI PstI. Then we ligated them together.  
  
 
<br>
 
<br>
 
<div style="display: block; height: 250pt;">
 
<div style="display: block; height: 250pt;">
−
[[File:131415.png|600px|thumb|left|'''Fig.2''' The combination of Ompa-N-scfv]]
+
[[File:131415.png|600px|thumb|left|'''Fig.2''' The combination of OmpA-N-scFv]]
−
[[File:ompascfv.png|250px|thumb|left|'''Fig.3''' Ompa-N-scfv]]
+
[[File:ompascfv.png|250px|thumb|left|'''Fig.3''' OmpA-N-scFv]]
 
</div>
 
</div>
 
<br><br>
 
<br><br>
 +
 +
<html>
 +
Introduction of basic parts:
 +
<br>
 +
<a href="https://parts.igem.org/wiki/index.php?title=Part:BBa_K1694015">OmpA-Anti-HER2 </a><br>
 +
</html>
 +
 +
 +
  
 
<h1>'''Experiment:'''</h1>
 
<h1>'''Experiment:'''</h1>
  
−
[[File:OH.png|200px|thumb|left|'''Fig.4''' The PCR result of the Lpp-OmpA-N+scFv. The DNA sequence length is around 1000~1200 bp, so the PCR products should appear at 1200~1400 bp.]]  
+
[[File:OH.png|200px|thumb|left|'''Fig.4''' The PCR result of the Lpp-OmpA-N+scFv. The DNA sequence length is 1026 bp, so the PCR products should appear at 1200~1400 bp.]]  
  
−
After receiving the DNA sequences from the gene synthesis company, we recombined each OmpA-N-scFv gene to PSB1C3 backbones and conducted a PCR experiment to check the size of each of the OmpA-N-scFvs. The DNA sequence length of the OmpA-N-scFvs are around 1000~1200 bp. In this PCR experiment, the OmpA-N-scFv products size should be near at 1200~1400 bp. The Fig.4 showed the correct size of the scFv, and proved that we successful ligated the scFv sequence onto an ideal backbone.
+
After receiving the DNA sequences from the gene synthesis company, we recombined each OmpA-N-scFv gene to pSB1C3 backbones and conducted a PCR experiment to check the size of each of the OmpA-N-scFvs. The length of OmpA-N-scFv DNA sequence is around 1000~1200 bp. In this PCR experiment, the OmpA-N-scFv products size should be near at 1200~1400 bp. The Fig.4 showed the correct size of the scFv, and proved that we successfully ligated the scFv sequence onto an ideal backbone.
  
−
[[File:OmpA-H.png|600px|thumb|center|'''Fig.5''' OmpA-N-scFv(Anti-HER2)]]  
+
[[File:OmpA-H.png|600px|thumb|center|'''Fig.5''' OmpA-N-scFv (anti-HER2)]]  
  
  

Latest revision as of 07:43, 22 September 2015

OmpA-scFv(Anti-HER2)


Introduction:

Fig.1 OmpA-N-scFv (anti-HER2)

To display the scFv outside the E. coli, we used Lipoprotein-Outer membrane protein A (Lpp-OmpA). According to the paper reference, we chose the first 9 amino acid of Lpp and the 46~159 amino acid of OmpA.
In order to easily change various scFv DNA sequence, we added a NcoI restriction site between OmpA and scFv. When designing XbaI-SpeI restriction site between Lpp-OmpA and scFv, it will cause a mixed site. Therefore, the NcoI restriction site rather than the EX-SP restriction site was designed.


The Fig.2 showed how we design NcoI restriction site. First, we digest Lpp-OmpA part with EcoRI and NcoI, scFv part with NcoI PstI. Then we ligated them together.


Fig.2 The combination of OmpA-N-scFv
Fig.3 OmpA-N-scFv



Introduction of basic parts:
OmpA-Anti-HER2



Experiment:

Fig.4 The PCR result of the Lpp-OmpA-N+scFv. The DNA sequence length is 1026 bp, so the PCR products should appear at 1200~1400 bp.

After receiving the DNA sequences from the gene synthesis company, we recombined each OmpA-N-scFv gene to pSB1C3 backbones and conducted a PCR experiment to check the size of each of the OmpA-N-scFvs. The length of OmpA-N-scFv DNA sequence is around 1000~1200 bp. In this PCR experiment, the OmpA-N-scFv products size should be near at 1200~1400 bp. The Fig.4 showed the correct size of the scFv, and proved that we successfully ligated the scFv sequence onto an ideal backbone.

Fig.5 OmpA-N-scFv (anti-HER2)


Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    INCOMPATIBLE WITH RFC[21]
    Illegal BglII site found at 678
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    INCOMPATIBLE WITH RFC[25]
    Illegal NgoMIV site found at 388
  • 1000
    COMPATIBLE WITH RFC[1000]